Yuri F. Pastukhov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuri F. Pastukhov has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Irina V. Ekimova
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia
19 shared publications I. V. Guzhova
Russian Academy of Sciences
6 shared publications- Mikhail A. Guzeev
Russian Academy of Sciences
6 shared publications - Valentina V. Simonova
Russian Academy of Sciences
5 shared publications - Irina V. Romanova
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia
3 shared publications - Ksenia V. Lapshina
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia
3 shared publications
Latest Publications
- Open Access
- 18 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (8) , 4464
Chaperone Hsp70 (HSPA1) Is Involved in the Molecular Mechanisms of Sleep Cycle Integration
The molecular mechanisms of sleep cycle integration at the beginning and the end of the inactive period are not clear. Sleep cycles with a predominance of deep slow-wave sleep (SWS) seem to be associated with accelerated protein synthesis in the brain. The inducible Hsp70 chaperone corrects protein conformational changes and has protective properties. This research explores (1) whether the Hspa1 gene encoding Hsp70 protein activates during the daily rapid-eye-movement sleep (REMS) maximum, and (2) whether a lower daily deep SWS maximum affects the Hspa1 expression level during the subsequent REMS. Combining polysomnography in male Wistar rats, RT-qPCR, and Western blotting, we reveal a three-fold Hspa1 upregulation in the nucleus reticularis pontis oralis, which regulates REMS. Hspa1 expression increases during the daily REMS maximum, 5–7 h after the natural peak of deep SWS. Using short-term selective REMS deprivation, we demonstrate that REMS rebound after deprivation exceeds the natural daily maximum, but it is not accompanied by Hspa1 upregulation. The results suggest that a high proportion of deep SWS, usually observed after sleep onset, is a necessary condition for Hspa1 upregulation during subsequent REMS. The data obtained can inform the understanding of the molecular mechanisms integrating SWS and REMS and key biological function(s) of sleep.
- 18 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (8) , 4464
Open AccessChaperone Hsp70 (HSPA1) Is Involved in the Molecular Mechanisms of Sleep Cycle Integration
The molecular mechanisms of sleep cycle integration at the beginning and the end of the inactive period are not clear. Sleep cycles with a predominance of deep slow-wave sleep (SWS) seem to be associated with accelerated protein synthesis in the brain. The inducible Hsp70 chaperone corrects protein conformational changes and has protective properties. This research explores (1) whether the Hspa1 gene encoding Hsp70 protein activates during the daily rapid-eye-movement sleep (REMS) maximum, and (2) whether a lower daily deep SWS maximum affects the Hspa1 expression level during the subsequent REMS. Combining polysomnography in male Wistar rats, RT-qPCR, and Western blotting, we reveal a three-fold Hspa1 upregulation in the nucleus reticularis pontis oralis, which regulates REMS. Hspa1 expression increases during the daily REMS maximum, 5–7 h after the natural peak of deep SWS. Using short-term selective REMS deprivation, we demonstrate that REMS rebound after deprivation exceeds the natural daily maximum, but it is not accompanied by Hspa1 upregulation. The results suggest that a high proportion of deep SWS, usually observed after sleep onset, is a necessary condition for Hspa1 upregulation during subsequent REMS. The data obtained can inform the understanding of the molecular mechanisms integrating SWS and REMS and key biological function(s) of sleep.
- 1 July 2020
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 10 (3) , 254-259
U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinson’s Disease in Aged Rats
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease that is closely associated with aging. It is considered incurable due to its late diagnosis and the use of symptomatic treatment, which cannot alter the molecular mechanisms of sleep disruption nor the neurodegenerative processes that develop with aging and PD progression. The present study assesses the therapeutic potential of a novel chaperone inducer, U-133 (acetyl 2,3,7-tris-O-glucoside echinochrome), in the preclinical stage of PD modelled in aged rats via inhibition of the proteasomal system in the brain. U-133 is a derivative of the sea-urchin pigment echinochrome (2,3,5,7,8-pentahydroxy-1,4-naphthoquinone). It is produced by glycosylation, which possesses neuroprotective, antioxidant, and anticancer properties. The administration of U-133, which induces the synthesis of Hsp 70i and HSP 40 heat-shock proteins in the brain, precludes an increase in the light-sleep (drowsiness) stage and a decrease in the total time of deep, slow-wave sleep, both of which occur with the progression of the preclinical stage of PD modelled in aged Wistar rats. Deep, slow-wave sleep is thought to promote glymphatic clearance and to accelerate protein synthesis. Thus, the U-133-induced increase in the proportion of deep, slow-wave sleep as compared to the preclinical model is considered to have a neuroprotective effect that contributes to the intensification of the restorative function of neurons and counteracts the progression of neurodegeneration.
- 1 July 2020
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 10 (3) , 254-259
U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinson’s Disease in Aged Rats
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease that is closely associated with aging. It is considered incurable due to its late diagnosis and the use of symptomatic treatment, which cannot alter the molecular mechanisms of sleep disruption nor the neurodegenerative processes that develop with aging and PD progression. The present study assesses the therapeutic potential of a novel chaperone inducer, U-133 (acetyl 2,3,7-tris-O-glucoside echinochrome), in the preclinical stage of PD modelled in aged rats via inhibition of the proteasomal system in the brain. U-133 is a derivative of the sea-urchin pigment echinochrome (2,3,5,7,8-pentahydroxy-1,4-naphthoquinone). It is produced by glycosylation, which possesses neuroprotective, antioxidant, and anticancer properties. The administration of U-133, which induces the synthesis of Hsp 70i and HSP 40 heat-shock proteins in the brain, precludes an increase in the light-sleep (drowsiness) stage and a decrease in the total time of deep, slow-wave sleep, both of which occur with the progression of the preclinical stage of PD modelled in aged Wistar rats. Deep, slow-wave sleep is thought to promote glymphatic clearance and to accelerate protein synthesis. Thus, the U-133-induced increase in the proportion of deep, slow-wave sleep as compared to the preclinical model is considered to have a neuroprotective effect that contributes to the intensification of the restorative function of neurons and counteracts the progression of neurodegeneration.
- 1 November 2018
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 54 (6) , 494-497
The Sleep–Wake Cycle and Molecular Chaperones: New Evidence in Support of the Hypothesis of the Critical Function of Paradoxical Sleep
- 1 November 2018
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 54 (6) , 494-497
The Sleep–Wake Cycle and Molecular Chaperones: New Evidence in Support of the Hypothesis of the Critical Function of Paradoxical Sleep
- Open Access
- 1 January 2018
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 118 (4) , 14-20
Changes in characteristics of sleep-wake cycle and motor activity at the preclinical stage of Parkinson's disease in old rats
Medical article медицинская статья
- 1 January 2018
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 118 (4) , 14-20
Open AccessChanges in characteristics of sleep-wake cycle and motor activity at the preclinical stage of Parkinson's disease in old rats
Medical article медицинская статья
- 1 September 2017
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 53 (5) , 431-434
Signs of sleep and behavior disorders indicating the initial stage of neurodegeneration in a rat model of Parkinson’s disease
- 1 September 2017
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 53 (5) , 431-434
Signs of sleep and behavior disorders indicating the initial stage of neurodegeneration in a rat model of Parkinson’s disease
- 1 September 2017
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 53 (5) , 435-438
Functional assessment of the nigrostriatal system in a rat preclinical model of Parkinson’s disease
- 1 September 2017
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 53 (5) , 435-438
Functional assessment of the nigrostriatal system in a rat preclinical model of Parkinson’s disease
- 1 September 2017
- Published by Pleiades Publishing Ltd in Doklady Biological Sciences
- Vol. 476 (1) , 188-190
Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson’s disease
An experimental model of the preclinical stage of Parkinson's disease was induced by double intranasal administration of the proteasome inhibitor lactacystin. The results demonstrated signs of cognitive impairments expressed as impaired non-associative learning. This was related to degeneration of one-third of dopaminergic neurons in the ventral tegmental area of the midbrain and their axons in the dorsolateral prefrontal cortex. Impairment of non-associative learning may be an early non-motor marker of Parkinson's disease indicating the start of neurodegenerative processes in the dopaminergic mesocortical system of the brain.
- 1 September 2017
- Published by Pleiades Publishing Ltd in Doklady Biological Sciences
- Vol. 476 (1) , 188-190
Impairment of non-associative learning in a rat experimental model of preclinical stage of Parkinson’s disease
An experimental model of the preclinical stage of Parkinson's disease was induced by double intranasal administration of the proteasome inhibitor lactacystin. The results demonstrated signs of cognitive impairments expressed as impaired non-associative learning. This was related to degeneration of one-third of dopaminergic neurons in the ventral tegmental area of the midbrain and their axons in the dorsolateral prefrontal cortex. Impairment of non-associative learning may be an early non-motor marker of Parkinson's disease indicating the start of neurodegenerative processes in the dopaminergic mesocortical system of the brain.
- 1 November 2016
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 52 (6) , 463-474
Changes in sleep characteristics of rat preclinical model of Parkinson’s disease based on attenuation of the ubiquitin—proteasome system activity in the brain
Numerous experimental and epidemiological data indicate a high significance of environmental neurotoxins, specifically, inhibitors of the ubiquitin–proteasome system, in pathogenesis of Parkinson’s disease (PD). To develop a preclinical model of PD in rats we used a technique of intranasal administration of lactacystin, a natural proteasome inhibitor, into the brain. It was found that three weeks after the first lactacystin administration it induced a little degeneration of dopaminergic neurons in the olfactory bulb and substantia nigra pars compacta without any olfactory dysfunction and motor behavior disorders. Besides, its effect led to the appearance of some signs of sleep disorders: increased somnolence (especially in the dark, active daily phase), fragmentation of slow-wave sleep, decreased EEG delta rhythm during slow-wave sleep. These signs share some similarity with PD and could be useful in clinical studies for the quick search for polysomnographic markers of the early PD stage.
- 1 November 2016
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 52 (6) , 463-474
Changes in sleep characteristics of rat preclinical model of Parkinson’s disease based on attenuation of the ubiquitin—proteasome system activity in the brain
Numerous experimental and epidemiological data indicate a high significance of environmental neurotoxins, specifically, inhibitors of the ubiquitin–proteasome system, in pathogenesis of Parkinson’s disease (PD). To develop a preclinical model of PD in rats we used a technique of intranasal administration of lactacystin, a natural proteasome inhibitor, into the brain. It was found that three weeks after the first lactacystin administration it induced a little degeneration of dopaminergic neurons in the olfactory bulb and substantia nigra pars compacta without any olfactory dysfunction and motor behavior disorders. Besides, its effect led to the appearance of some signs of sleep disorders: increased somnolence (especially in the dark, active daily phase), fragmentation of slow-wave sleep, decreased EEG delta rhythm during slow-wave sleep. These signs share some similarity with PD and could be useful in clinical studies for the quick search for polysomnographic markers of the early PD stage.
- 1 January 2016
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 52 (1) , 87-101
Slow-wave sleep and molecular chaperones
Since long ago, one of the most vital issues mankind is concerned about is why spending almost one-third of human lives for sleep. This review addresses the major function of slow-wave sleep (SWS)...
- 1 January 2016
- Published by Pleiades Publishing Ltd in Journal of Evolutionary Biochemistry and Physiology
- Vol. 52 (1) , 87-101
Slow-wave sleep and molecular chaperones
Since long ago, one of the most vital issues mankind is concerned about is why spending almost one-third of human lives for sleep. This review addresses the major function of slow-wave sleep (SWS)...
- 1 March 2015
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 461 (1) , 76-79
Chaperone Hsp70 is involved in the molecular mechanisms of slow wave sleep regulation
- 1 March 2015
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 461 (1) , 76-79
Chaperone Hsp70 is involved in the molecular mechanisms of slow wave sleep regulation